{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:32:20Z","timestamp":1793140340705,"version":"4.5.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018703","name":"HORIZON EUROPE European Innovation Council","doi-asserted-by":"publisher","award":["101080329"],"award-info":[{"award-number":["101080329"]}],"id":[{"id":"10.13039\/100018703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["LA\/P\/0087\/2020"],"award-info":[{"award-number":["LA\/P\/0087\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/Multi\/04462\/2020"],"award-info":[{"award-number":["UIDB\/Multi\/04462\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Health Initiative","doi-asserted-by":"publisher","award":["101132946"],"award-info":[{"award-number":["101132946"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Consiglio Nazionale Delle Ricerche","id":[{"id":"https:\/\/ror.org\/04zaypm56","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00125-026-06774-7","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T12:59:13Z","timestamp":1781960353000},"page":"3088-3104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Metabolic drivers of MASLD and MASH: from hormonal imbalance to fibrosis"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2594-1651","authenticated-orcid":false,"given":"Amalia","family":"Gastaldelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2753-8487","authenticated-orcid":false,"given":"Egeria","family":"Scoditti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2549-0275","authenticated-orcid":false,"given":"Maria Paula","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"issue":"7","key":"6774_CR1","doi-asserted-by":"publisher","first-page":"e2407","DOI":"10.1210\/clinem\/dgaf094","volume":"110","author":"A Gastaldelli","year":"2025","unstructured":"Gastaldelli A, Newsome PN (2025) NAFLD vs MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)-why the need for a change of nomenclature? J Clin Endocrinol Metab 110(7):e2407\u2013e2410. https:\/\/doi.org\/10.1210\/clinem\/dgaf094","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"6774_CR2","doi-asserted-by":"publisher","first-page":"e186420","DOI":"10.1172\/JCI186420","volume":"135","author":"GR Steinberg","year":"2025","unstructured":"Steinberg GR, Carpentier AC, Wang D (2025) MASH: the nexus of metabolism, inflammation, and fibrosis. J Clin Invest 135(18):e186420. https:\/\/doi.org\/10.1172\/JCI186420","journal-title":"J Clin Invest"},{"issue":"7","key":"6774_CR3","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1053\/j.gastro.2019.12.054","volume":"158","author":"V Azzu","year":"2020","unstructured":"Azzu V, Vacca M, Virtue S, Allison M, Vidal-Puig A (2020) Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in nonalcoholic fatty liver disease. Gastroenterology 158(7):1899\u20131912. https:\/\/doi.org\/10.1053\/j.gastro.2019.12.054","journal-title":"Gastroenterology"},{"issue":"5","key":"6774_CR4","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.cmet.2017.04.015","volume":"25","author":"BH Goodpaster","year":"2017","unstructured":"Goodpaster BH, Sparks LM (2017) Metabolic flexibility in health and disease. Cell Metab 25(5):1027\u20131036. https:\/\/doi.org\/10.1016\/j.cmet.2017.04.015","journal-title":"Cell Metab"},{"issue":"15","key":"6774_CR5","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1042\/CS20170261","volume":"131","author":"B Brouwers","year":"2017","unstructured":"Brouwers B, Schrauwen-Hinderling VB, Jelenik T et al (2017) Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes. Clin Sci 131(15):1905\u20131917. https:\/\/doi.org\/10.1042\/CS20170261","journal-title":"Clin Sci"},{"issue":"7","key":"6774_CR6","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.2337\/diabetes.51.7.2029","volume":"51","author":"V van Harmelen","year":"2002","unstructured":"van Harmelen V, Dicker A, Ryden M et al (2002) Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes 51(7):2029\u20132036. https:\/\/doi.org\/10.2337\/diabetes.51.7.2029","journal-title":"Diabetes"},{"issue":"9","key":"6774_CR7","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00125-002-0873-y","volume":"45","author":"KN Frayn","year":"2002","unstructured":"Frayn KN (2002) Adipose tissue as a buffer for daily lipid flux. Diabetologia 45(9):1201\u20131210. https:\/\/doi.org\/10.1007\/s00125-002-0873-y","journal-title":"Diabetologia"},{"issue":"4","key":"6774_CR8","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","volume":"98","author":"MC Petersen","year":"2018","unstructured":"Petersen MC, Shulman GI (2018) Mechanisms of insulin action and insulin resistance. Physiol Rev 98(4):2133\u20132223. https:\/\/doi.org\/10.1152\/physrev.00063.2017","journal-title":"Physiol Rev"},{"issue":"4","key":"6774_CR9","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2337\/db16-1167","volume":"66","author":"A Gastaldelli","year":"2017","unstructured":"Gastaldelli A, Gaggini M, DeFronzo RA (2017) Role of adipose tissue insulin resistance in the natural history of type 2 diabetes: results from the San Antonio metabolism study. Diabetes 66(4):815\u2013822. https:\/\/doi.org\/10.2337\/db16-1167","journal-title":"Diabetes"},{"issue":"11","key":"6774_CR10","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1111\/liv.15377","volume":"42","author":"C Saponaro","year":"2022","unstructured":"Saponaro C, Sabatini S, Gaggini M et al (2022) Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals. Liver Int Off J Int Assoc Study Liver 42(11):2418\u20132427. https:\/\/doi.org\/10.1111\/liv.15377","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"5","key":"6774_CR11","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI23621","volume":"115","author":"KL Donnelly","year":"2005","unstructured":"Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115(5):1343\u20131351. https:\/\/doi.org\/10.1172\/JCI23621","journal-title":"J Clin Invest"},{"issue":"2","key":"6774_CR12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1053\/j.gastro.2007.04.068","volume":"133","author":"A Gastaldelli","year":"2007","unstructured":"Gastaldelli A, Cusi K, Pettiti M et al (2007) Relationship between hepatic\/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133(2):496\u2013506. https:\/\/doi.org\/10.1053\/j.gastro.2007.04.068","journal-title":"Gastroenterology"},{"issue":"9","key":"6774_CR13","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.2337\/db21-1097","volume":"71","author":"RZ Ye","year":"2022","unstructured":"Ye RZ, Montastier E, Noll C et al (2022) Total postprandial hepatic nonesterified and dietary fatty acid uptake is increased and insufficiently curbed by adipose tissue fatty acid trapping in prediabetes with overweight. Diabetes 71(9):1891\u20131901. https:\/\/doi.org\/10.2337\/db21-1097","journal-title":"Diabetes"},{"issue":"4","key":"6774_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.nucmedbio.2006.02.003","volume":"33","author":"L Guiducci","year":"2006","unstructured":"Guiducci L, Jarvisalo M, Kiss J et al (2006) [11C]palmitate kinetics across the splanchnic bed in arterial, portal and hepatic venous plasma during fasting and euglycemic hyperinsulinemia. Nucl Med Biol 33(4):521\u2013528. https:\/\/doi.org\/10.1016\/j.nucmedbio.2006.02.003","journal-title":"Nucl Med Biol"},{"issue":"11","key":"6774_CR15","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1172\/JCI21047","volume":"113","author":"S Nielsen","year":"2004","unstructured":"Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD (2004) Splanchnic lipolysis in human obesity. J Clin Invest 113(11):1582\u20131588. https:\/\/doi.org\/10.1172\/JCI21047","journal-title":"J Clin Invest"},{"issue":"11","key":"6774_CR16","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s001250051075","volume":"41","author":"JR Zierath","year":"1998","unstructured":"Zierath JR, Livingston JN, Thorne A et al (1998) Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. Diabetologia 41(11):1343\u20131354. https:\/\/doi.org\/10.1007\/s001250051075","journal-title":"Diabetologia"},{"issue":"10","key":"6774_CR17","doi-asserted-by":"publisher","first-page":"E209","DOI":"10.1210\/jc.2010-0520","volume":"95","author":"A Thorne","year":"2010","unstructured":"Thorne A, Lofgren P, Hoffstedt J (2010) Increased visceral adipocyte lipolysis\u2013a pathogenic role in nonalcoholic fatty liver disease? J Clin Endocrinol Metab 95(10):E209-213. https:\/\/doi.org\/10.1210\/jc.2010-0520","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 2","key":"6774_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1467-789X.2012.01035.x","volume":"13","author":"F Item","year":"2012","unstructured":"Item F, Konrad D (2012) Visceral fat and metabolic inflammation: the portal theory revisited. Obes Rev 13(Suppl 2):30\u201339. https:\/\/doi.org\/10.1111\/j.1467-789X.2012.01035.x","journal-title":"Obes Rev"},{"issue":"5","key":"6774_CR19","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","volume":"70","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G (2021) Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 70(5):962\u2013969. https:\/\/doi.org\/10.1136\/gutjnl-2020-322572","journal-title":"Gut"},{"key":"6774_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.03.006","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Price JK et al (2024) The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2024.03.006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"6774_CR21","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/hep.28985","volume":"65","author":"F Bril","year":"2017","unstructured":"Bril F, Barb D, Portillo-Sanchez P et al (2017) Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology 65(4):1132\u20131144. https:\/\/doi.org\/10.1002\/hep.28985","journal-title":"Hepatology"},{"issue":"4","key":"6774_CR22","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s00125-005-1682-x","volume":"48","author":"E Bugianesi","year":"2005","unstructured":"Bugianesi E, Gastaldelli A, Vanni E et al (2005) Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48(4):634\u2013642. https:\/\/doi.org\/10.1007\/s00125-005-1682-x","journal-title":"Diabetologia"},{"issue":"1","key":"6774_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJM199201023260104","volume":"326","author":"A Mitrakou","year":"1992","unstructured":"Mitrakou A, Kelley D, Mokan M et al (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326(1):22\u201329. https:\/\/doi.org\/10.1056\/NEJM199201023260104","journal-title":"N Engl J Med"},{"issue":"1","key":"6774_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00125-003-1263-9","volume":"47","author":"A Gastaldelli","year":"2004","unstructured":"Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA, San Antonio metabolism s (2004) Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47(1):31\u201339. https:\/\/doi.org\/10.1007\/s00125-003-1263-9","journal-title":"Diabetologia"},{"key":"6774_CR25","doi-asserted-by":"publisher","first-page":"8994","DOI":"10.1038\/ncomms9994","volume":"7","author":"T Hyotylainen","year":"2016","unstructured":"Hyotylainen T, Jerby L, Petaja EM et al (2016) Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease. Nat Commun 7:8994. https:\/\/doi.org\/10.1038\/ncomms9994","journal-title":"Nat Commun"},{"issue":"11","key":"6774_CR26","doi-asserted-by":"publisher","first-page":"101820","DOI":"10.1016\/j.xcrm.2024.101820","volume":"5","author":"S Sabatini","year":"2024","unstructured":"Sabatini S, Sen P, Carli F et al (2024) Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis. Cell Rep Med 5(11):101820. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101820","journal-title":"Cell Rep Med"},{"issue":"6","key":"6774_CR27","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.cmet.2011.11.004","volume":"14","author":"NE Sunny","year":"2011","unstructured":"Sunny NE, Parks EJ, Browning JD, Burgess SC (2011) Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 14(6):804\u2013810. https:\/\/doi.org\/10.1016\/j.cmet.2011.11.004","journal-title":"Cell Metab"},{"issue":"11","key":"6774_CR28","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1016\/j.cmet.2024.07.023","volume":"36","author":"KF Petersen","year":"2024","unstructured":"Petersen KF, Dufour S, Mehal WZ, Shulman GI (2024) Glucagon promotes increased hepatic mitochondrial oxidation and pyruvate carboxylase flux in humans with fatty liver disease. Cell Metab 36(11):2359-2366 e2353. https:\/\/doi.org\/10.1016\/j.cmet.2024.07.023","journal-title":"Cell Metab"},{"issue":"5","key":"6774_CR29","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1053\/gast.2001.23256","volume":"120","author":"AJ Sanyal","year":"2001","unstructured":"Sanyal AJ, Campbell-Sargent C, Mirshahi F et al (2001) Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120(5):1183\u20131192. https:\/\/doi.org\/10.1053\/gast.2001.23256","journal-title":"Gastroenterology"},{"issue":"5","key":"6774_CR30","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","volume":"21","author":"C Koliaki","year":"2015","unstructured":"Koliaki C, Szendroedi J, Kaul K et al (2015) Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab 21(5):739\u2013746. https:\/\/doi.org\/10.1016\/j.cmet.2015.04.004","journal-title":"Cell Metab"},{"issue":"4","key":"6774_CR31","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.tem.2016.11.006","volume":"28","author":"NE Sunny","year":"2017","unstructured":"Sunny NE, Bril F, Cusi K (2017) Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies. Trends Endocrinol Metab 28(4):250\u2013260. https:\/\/doi.org\/10.1016\/j.tem.2016.11.006","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"6774_CR32","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/hep.32324","volume":"76","author":"MP Moore","year":"2022","unstructured":"Moore MP, Cunningham RP, Meers GM et al (2022) Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD. Hepatology 76(5):1452\u20131465. https:\/\/doi.org\/10.1002\/hep.32324","journal-title":"Hepatology"},{"key":"6774_CR33","doi-asserted-by":"publisher","first-page":"105532","DOI":"10.1016\/j.ebiom.2024.105532","volume":"111","author":"H Castane","year":"2025","unstructured":"Castane H, Jimenez-Franco A, Hernandez-Aguilera A et al (2025) Multi-omics profiling reveals altered mitochondrial metabolism in adipose tissue from patients with metabolic dysfunction-associated steatohepatitis. EBioMedicine 111:105532. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105532","journal-title":"EBioMedicine"},{"issue":"6","key":"6774_CR34","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.jhep.2022.08.010","volume":"77","author":"K Pafili","year":"2022","unstructured":"Pafili K, Kahl S, Mastrototaro L et al (2022) Mitochondrial respiration is decreased in visceral but not subcutaneous adipose tissue in obese individuals with fatty liver disease. J Hepatol 77(6):1504\u20131514. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.010","journal-title":"J Hepatol"},{"issue":"2","key":"6774_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s42255-024-00978-0","volume":"6","author":"W Xia","year":"2024","unstructured":"Xia W, Veeragandham P, Cao Y et al (2024) Obesity causes mitochondrial fragmentation and dysfunction in white adipocytes due to RalA activation. Nat Metab 6(2):273\u2013289. https:\/\/doi.org\/10.1038\/s42255-024-00978-0","journal-title":"Nat Metab"},{"issue":"2","key":"6774_CR36","doi-asserted-by":"publisher","first-page":"E209","DOI":"10.1210\/jc.2013-3042","volume":"99","author":"X Yin","year":"2014","unstructured":"Yin X, Lanza IR, Swain JM, Sarr MG, Nair KS, Jensen MD (2014) Adipocyte mitochondrial function is reduced in human obesity independent of fat cell size. J Clin Endocrinol Metab 99(2):E209-216. https:\/\/doi.org\/10.1210\/jc.2013-3042","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"6774_CR37","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cmet.2024.05.003","volume":"36","author":"P Horn","year":"2024","unstructured":"Horn P, Tacke F (2024) Metabolic reprogramming in liver fibrosis. Cell Metab 36(7):1439\u20131455. https:\/\/doi.org\/10.1016\/j.cmet.2024.05.003","journal-title":"Cell Metab"},{"issue":"10","key":"6774_CR38","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/j.celrep.2017.05.035","volume":"19","author":"KW Ter Horst","year":"2017","unstructured":"Ter Horst KW, Gilijamse PW, Versteeg RI et al (2017) Hepatic diacylglycerol-associated protein kinase cepsilon translocation links hepatic steatosis to hepatic insulin resistance in humans. Cell Rep 19(10):1997\u20132004. https:\/\/doi.org\/10.1016\/j.celrep.2017.05.035","journal-title":"Cell Rep"},{"issue":"1","key":"6774_CR39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nm.2277","volume":"17","author":"WL Holland","year":"2011","unstructured":"Holland WL, Miller RA, Wang ZV et al (2011) Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17(1):55\u201363. https:\/\/doi.org\/10.1038\/nm.2277","journal-title":"Nat Med"},{"issue":"813","key":"6774_CR40","doi-asserted-by":"publisher","first-page":"eads9470","DOI":"10.1126\/scitranslmed.ads9470","volume":"17","author":"S Sharma","year":"2025","unstructured":"Sharma S, Prathigudupu V, Cable C et al (2025) Resolving fibrosis by stimulating HSC-dependent extracellular matrix degradation. Sci Transl Med 17(813):eads9470. https:\/\/doi.org\/10.1126\/scitranslmed.ads9470","journal-title":"Sci Transl Med"},{"issue":"7783","key":"6774_CR41","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","volume":"575","author":"P Ramachandran","year":"2019","unstructured":"Ramachandran P, Dobie R, Wilson-Kanamori JR et al (2019) Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature 575(7783):512\u2013518. https:\/\/doi.org\/10.1038\/s41586-019-1631-3","journal-title":"Nature"},{"issue":"2","key":"6774_CR42","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","volume":"68","author":"D Schuppan","year":"2018","unstructured":"Schuppan D, Surabattula R, Wang XY (2018) Determinants of fibrosis progression and regression in NASH. J Hepatol 68(2):238\u2013250. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.012","journal-title":"J Hepatol"},{"issue":"9","key":"6774_CR43","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","volume":"71","author":"TG Simon","year":"2022","unstructured":"Simon TG, Roelstraete B, Hagstrom H, Sundstrom J, Ludvigsson JF (2022) Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut 71(9):1867\u20131875. https:\/\/doi.org\/10.1136\/gutjnl-2021-325724","journal-title":"Gut"},{"issue":"12","key":"6774_CR44","doi-asserted-by":"publisher","first-page":"6420","DOI":"10.3390\/ijms25126420","volume":"25","author":"L De la Cruz-Color","year":"2024","unstructured":"De la Cruz-Color L, Dominguez-Rosales JA, Maldonado-Gonzalez M et al (2024) Evidence that peripheral leptin resistance in omental adipose tissue and liver correlates with MASLD in humans. Int J Mol Sci 25(12):6420. https:\/\/doi.org\/10.3390\/ijms25126420","journal-title":"Int J Mol Sci"},{"issue":"11","key":"6774_CR45","doi-asserted-by":"publisher","first-page":"G1310","DOI":"10.1152\/ajpgi.00365.2011","volume":"302","author":"K Miura","year":"2012","unstructured":"Miura K, Yang L, van Rooijen N, Ohnishi H, Seki E (2012) Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol 302(11):G1310-1321. https:\/\/doi.org\/10.1152\/ajpgi.00365.2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"6","key":"6774_CR46","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.3390\/jcm10061248","volume":"10","author":"I Coelho","year":"2021","unstructured":"Coelho I, Duarte N, Macedo MP, Penha-Goncalves C (2021) Insights into macrophage\/monocyte-endothelial cell crosstalk in the liver: a role for trem-2. J Clin Med 10(6):1248. https:\/\/doi.org\/10.3390\/jcm10061248","journal-title":"J Clin Med"},{"key":"6774_CR47","doi-asserted-by":"publisher","first-page":"616044","DOI":"10.3389\/fimmu.2020.616044","volume":"11","author":"I Coelho","year":"2020","unstructured":"Coelho I, Duarte N, Barros A, Macedo MP, Penha-Goncalves C (2020) Trem-2 promotes emergence of restorative macrophages and endothelial cells during recovery from hepatic tissue damage. Front Immunol 11:616044. https:\/\/doi.org\/10.3389\/fimmu.2020.616044","journal-title":"Front Immunol"},{"issue":"6","key":"6774_CR48","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/hep.22848","volume":"49","author":"L Miele","year":"2009","unstructured":"Miele L, Valenza V, La Torre G et al (2009) Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49(6):1877\u20131887. https:\/\/doi.org\/10.1002\/hep.22848","journal-title":"Hepatology"},{"issue":"5","key":"6774_CR49","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2337\/db24-0481","volume":"74","author":"M Albiero","year":"2025","unstructured":"Albiero M, Migliozzi L, Boscaro C et al (2025) Padi4-dependent NETosis enables diet-induced gut hyperpermeability, translating dysbiosis into systemic inflammation and dysmetabolism. Diabetes 74(5):705\u2013719. https:\/\/doi.org\/10.2337\/db24-0481","journal-title":"Diabetes"},{"issue":"5","key":"6774_CR50","doi-asserted-by":"publisher","first-page":"E644","DOI":"10.1152\/ajpendo.00346.2024","volume":"329","author":"M Pradeau","year":"2025","unstructured":"Pradeau M, Beaulieu S, Paquet V et al (2025) Plasma and fecal bile acids profiles in metabolic dysfunction-associated steatotic liver disease with advanced fibrosis. Am J Physiol Endocrinol Metab 329(5):E644\u2013E654. https:\/\/doi.org\/10.1152\/ajpendo.00346.2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"6774_CR51","doi-asserted-by":"publisher","first-page":"103290","DOI":"10.1016\/j.ebiom.2021.103290","volume":"66","author":"G Xie","year":"2021","unstructured":"Xie G, Jiang R, Wang X et al (2021) Conjugated secondary 12alpha-hydroxylated bile acids promote liver fibrogenesis. EBioMedicine 66:103290. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103290","journal-title":"EBioMedicine"},{"issue":"3","key":"6774_CR52","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/hep.29892","volume":"68","author":"C Caussy","year":"2018","unstructured":"Caussy C, Hsu C, Lo MT et al (2018) Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology 68(3):918\u2013932. https:\/\/doi.org\/10.1002\/hep.29892","journal-title":"Hepatology"},{"issue":"1","key":"6774_CR53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2337\/diabetes.50.1.131","volume":"50","author":"MC Munoz","year":"2001","unstructured":"Munoz MC, Barbera A, Dominguez J, Fernandez-Alvarez J, Gomis R, Guinovart JJ (2001) Effects of tungstate, a new potential oral antidiabetic agent, in Zucker diabetic fatty rats. Diabetes 50(1):131\u2013138. https:\/\/doi.org\/10.2337\/diabetes.50.1.131","journal-title":"Diabetes"},{"issue":"7","key":"6774_CR54","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/dom.12272","volume":"16","author":"MJ Armstrong","year":"2014","unstructured":"Armstrong MJ, Hazlehurst JM, Hull D et al (2014) Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. Diabetes Obes Metab 16(7):651\u2013660. https:\/\/doi.org\/10.1111\/dom.12272","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"6774_CR55","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/oby.23503","volume":"30","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli A (2022) Measuring and estimating insulin resistance in clinical and research settings. Obesity (Silver Spring) 30(8):1549\u20131563. https:\/\/doi.org\/10.1002\/oby.23503","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"6774_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/hep.28287","volume":"63","author":"C Rosso","year":"2016","unstructured":"Rosso C, Mezzabotta L, Gaggini M et al (2016) Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology 63(1):107\u2013116. https:\/\/doi.org\/10.1002\/hep.28287","journal-title":"Hepatology"},{"key":"6774_CR57","doi-asserted-by":"publisher","unstructured":"Svegliati-Baroni G, Gaggini M, Carli F et al (2020) Mechanisms for increased risk of diabetes in chronic liver diseases. Liver Int 40(10):2489\u20132499. https:\/\/doi.org\/10.1111\/liv.14556","DOI":"10.1111\/liv.14556"},{"issue":"3","key":"6774_CR58","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.cmet.2025.12.004","volume":"38","author":"T Marjot","year":"2026","unstructured":"Marjot T, Smith K, Westcott F et al (2026) Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night. Cell Metab 38(3):474-492 e476. https:\/\/doi.org\/10.1016\/j.cmet.2025.12.004","journal-title":"Cell Metab"},{"issue":"5","key":"6774_CR59","doi-asserted-by":"publisher","first-page":"E616","DOI":"10.1152\/ajpendo.00294.2023","volume":"326","author":"T Gignac","year":"2024","unstructured":"Gignac T, Trepanier G, Pradeau M et al (2024) Metabolic-associated fatty liver disease is characterized by a post-oral glucose load hyperinsulinemia in individuals with mild metabolic alterations. Am J Physiol Endocrinol Metab 326(5):E616\u2013E625. https:\/\/doi.org\/10.1152\/ajpendo.00294.2023","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"6774_CR60","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.2337\/dc21-0545","volume":"44","author":"R Bizzotto","year":"2021","unstructured":"Bizzotto R, Trico D, Natali A et al (2021) New insights on the interactions between insulin clearance and the main glucose homeostasis mechanisms. Diabetes Care 44(9):2115\u20132123. https:\/\/doi.org\/10.2337\/dc21-0545","journal-title":"Diabetes Care"},{"key":"6774_CR61","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1146\/annurev-physiol-031622-043133","volume":"85","author":"SM Najjar","year":"2023","unstructured":"Najjar SM, Caprio S, Gastaldelli A (2023) Insulin clearance in health and disease. Annu Rev Physiol 85:363\u2013381. https:\/\/doi.org\/10.1146\/annurev-physiol-031622-043133","journal-title":"Annu Rev Physiol"},{"key":"6774_CR62","doi-asserted-by":"publisher","unstructured":"Patarrao RS, Meneses MJ, Ghadieh HE et al (2024) Insights into circulating CEACAM1 in insulin clearance and disease progression: evidence from the Portuguese PREVADIAB2 study. Eur J Clin Investig 54(Suppl 2):e14344. https:\/\/doi.org\/10.1111\/eci.14344","DOI":"10.1111\/eci.14344"},{"issue":"1","key":"6774_CR63","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/HEP.0000000000000710","volume":"83","author":"SA Harrison","year":"2026","unstructured":"Harrison SA, Dubourg J, Knott M, Colca J (2026) Hyperinsulinemia, an overlooked clue and potential way forward in metabolic dysfunction-associated steatotic liver disease. Hepatology 83(1):169\u2013177. https:\/\/doi.org\/10.1097\/HEP.0000000000000710","journal-title":"Hepatology"},{"key":"6774_CR64","doi-asserted-by":"publisher","first-page":"154776","DOI":"10.1016\/j.metabol.2021.154776","volume":"119","author":"A Lamprinou","year":"2021","unstructured":"Lamprinou A, Willmann C, Machann J et al (2021) Determinants of hepatic insulin clearance - Results from a Mendelian Randomization study. Metabolism 119:154776. https:\/\/doi.org\/10.1016\/j.metabol.2021.154776","journal-title":"Metabolism"},{"issue":"5","key":"6774_CR65","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1210\/jc.2018-01808","volume":"104","author":"KM Utzschneider","year":"2019","unstructured":"Utzschneider KM, Kahn SE, Polidori DC (2019) Hepatic insulin extraction in NAFLD is related to insulin resistance rather than liver fat content. J Clin Endocrinol Metab 104(5):1855\u20131865. https:\/\/doi.org\/10.1210\/jc.2018-01808","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6774_CR66","doi-asserted-by":"publisher","first-page":"G558","DOI":"10.1152\/ajpgi.00147.2024","volume":"327","author":"SAS Kjeldsen","year":"2024","unstructured":"Kjeldsen SAS, Werge MP, Grandt J et al (2024) Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease. Am J Physiol Gastrointest Liver Physiol 327(4):G558\u2013G570. https:\/\/doi.org\/10.1152\/ajpgi.00147.2024","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"5","key":"6774_CR67","doi-asserted-by":"publisher","first-page":"e200913","DOI":"10.1172\/JCI200913","volume":"136","author":"HE Christie","year":"2026","unstructured":"Christie HE, Mohan S, Egan AM et al (2026) Hepatic steatosis in humans is associated with preserved glucagon action on amino acid metabolism. J Clin Invest 136(5):e200913. https:\/\/doi.org\/10.1172\/JCI200913","journal-title":"J Clin Invest"},{"key":"6774_CR68","doi-asserted-by":"publisher","first-page":"101080","DOI":"10.1016\/j.molmet.2020.101080","volume":"42","author":"M Winther-Sorensen","year":"2020","unstructured":"Winther-Sorensen M, Galsgaard KD, Santos A et al (2020) Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis. Mol Metab 42:101080. https:\/\/doi.org\/10.1016\/j.molmet.2020.101080","journal-title":"Mol Metab"},{"issue":"1","key":"6774_CR69","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1172\/JCI60016","volume":"122","author":"RH Unger","year":"2012","unstructured":"Unger RH, Cherrington AD (2012) Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 122(1):4\u201312. https:\/\/doi.org\/10.1172\/JCI60016","journal-title":"J Clin Invest"},{"key":"6774_CR70","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.peptides.2017.11.016","volume":"100","author":"NJ Wewer Albrechtsen","year":"2018","unstructured":"Wewer Albrechtsen NJ (2018) Glucagon receptor signaling in metabolic diseases. Peptides 100:42\u201347. https:\/\/doi.org\/10.1016\/j.peptides.2017.11.016","journal-title":"Peptides"},{"issue":"10","key":"6774_CR71","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.2337\/db25-0209","volume":"74","author":"TM Cacciottolo","year":"2025","unstructured":"Cacciottolo TM, Lawler K, Mendez-Acevedo KM et al (2025) Glucagon receptor deficiency causes early-onset hepatic steatosis. Diabetes 74(10):1787\u20131801. https:\/\/doi.org\/10.2337\/db25-0209","journal-title":"Diabetes"},{"issue":"6","key":"6774_CR72","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1002\/hep.26988","volume":"59","author":"F Bril","year":"2014","unstructured":"Bril F, Lomonaco R, Orsak B et al (2014) Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology 59(6):2178\u20132187. https:\/\/doi.org\/10.1002\/hep.26988","journal-title":"Hepatology"},{"issue":"6","key":"6774_CR73","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/oby.20134","volume":"21","author":"G Boden","year":"2013","unstructured":"Boden G, Salehi S, Cheung P et al (2013) Comparison of in vivo effects of insulin on SREBP-1c activation and INSIG-1\/2 in rat liver and human and rat adipose tissue. Obesity (Silver Spring) 21(6):1208\u20131214. https:\/\/doi.org\/10.1002\/oby.20134","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"6774_CR74","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI134165","volume":"130","author":"GI Smith","year":"2020","unstructured":"Smith GI, Shankaran M, Yoshino M et al (2020) Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest 130(3):1453\u20131460. https:\/\/doi.org\/10.1172\/JCI134165","journal-title":"J Clin Invest"},{"issue":"6","key":"6774_CR75","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.cmet.2016.04.022","volume":"23","author":"PM Titchenell","year":"2016","unstructured":"Titchenell PM, Quinn WJ, Lu M et al (2016) Direct hepatocyte insulin signaling is required for lipogenesis but is dispensable for the suppression of glucose production. Cell Metab 23(6):1154\u20131166. https:\/\/doi.org\/10.1016\/j.cmet.2016.04.022","journal-title":"Cell Metab"},{"issue":"4","key":"6774_CR76","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1007\/s10620-017-4470-9","volume":"62","author":"CX Cai","year":"2017","unstructured":"Cai CX, Buddha H, Castelino-Prabhu S et al (2017) Activation of insulin-PI3K\/Akt-p70S6K pathway in hepatic stellate cells contributes to fibrosis in nonalcoholic steatohepatitis. Dig Dis Sci 62(4):968\u2013978. https:\/\/doi.org\/10.1007\/s10620-017-4470-9","journal-title":"Dig Dis Sci"},{"issue":"4","key":"6774_CR77","doi-asserted-by":"publisher","first-page":"49","DOI":"10.20517\/mtod.2024.59","volume":"4","author":"M Dodig","year":"2024","unstructured":"Dodig M, Li M, Dasarathy S et al (2024) Insulin increases type I collagen synthesis in hepatic stellate cells via alpha5beta1 integrin. Metab Target Organ Damage 4(4):49. https:\/\/doi.org\/10.20517\/mtod.2024.59","journal-title":"Metab Target Organ Damage"},{"issue":"5","key":"6774_CR78","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jhep.2019.06.031","volume":"71","author":"C Rosso","year":"2019","unstructured":"Rosso C, Kazankov K, Younes R et al (2019) Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. J Hepatol 71(5):1012\u20131021. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.031","journal-title":"J Hepatol"},{"issue":"4","key":"6774_CR79","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"HC Gerstein","year":"2012","unstructured":"ORIGIN Trial Investigators, Gerstein HC, Bosch J et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367(4):319\u2013328. https:\/\/doi.org\/10.1056\/NEJMoa1203858","journal-title":"N Engl J Med"},{"issue":"3","key":"6774_CR80","doi-asserted-by":"publisher","first-page":"E829","DOI":"10.1152\/ajpendo.00133.2006","volume":"292","author":"L Juurinen","year":"2007","unstructured":"Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvinen H (2007) Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 292(3):E829-835. https:\/\/doi.org\/10.1152\/ajpendo.00133.2006","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"6774_CR81","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli A, Cusi K, Fernandez Lando L, Bray R, Brouwers B, Rodriguez A (2022) Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 10(6):393\u2013406. https:\/\/doi.org\/10.1016\/S2213-8587(22)00070-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"6774_CR82","doi-asserted-by":"publisher","first-page":"e14177","DOI":"10.1111\/eci.14177","volume":"54","author":"S Zaidi","year":"2024","unstructured":"Zaidi S, Asalla S, Muturi HT et al (2024) Loss of CEACAM1 in hepatocytes causes hepatic fibrosis. Eur J Clin Investig 54(7):e14177. https:\/\/doi.org\/10.1111\/eci.14177","journal-title":"Eur J Clin Investig"},{"issue":"10","key":"6774_CR83","doi-asserted-by":"publisher","first-page":"e1912565","DOI":"10.1001\/jamanetworkopen.2019.12565","volume":"2","author":"DE Kleiner","year":"2019","unstructured":"Kleiner DE, Brunt EM, Wilson LA et al (2019) Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw Open 2(10):e1912565. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.12565","journal-title":"JAMA Netw Open"},{"issue":"5","key":"6774_CR84","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1210\/clinem\/dgac660","volume":"108","author":"S Kalavalapalli","year":"2023","unstructured":"Kalavalapalli S, Leiva EG, Lomonaco R et al (2023) Adipose tissue insulin resistance predicts the severity of liver fibrosis in patients with type 2 diabetes and NAFLD. J Clin Endocrinol Metab 108(5):1192\u20131201. https:\/\/doi.org\/10.1210\/clinem\/dgac660","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6774_CR85","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/hep.23116","volume":"50","author":"A Gastaldelli","year":"2009","unstructured":"Gastaldelli A, Harrison SA, Belfort-Aguilar R et al (2009) Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50(4):1087\u20131093. https:\/\/doi.org\/10.1002\/hep.23116","journal-title":"Hepatology"},{"issue":"4","key":"6774_CR86","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/hep.25805","volume":"56","author":"LN Bell","year":"2012","unstructured":"Bell LN, Wang J, Muralidharan S et al (2012) Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology 56(4):1311\u20131318. https:\/\/doi.org\/10.1002\/hep.25805","journal-title":"Hepatology"},{"issue":"3","key":"6774_CR87","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/hep.25739","volume":"56","author":"G Musso","year":"2012","unstructured":"Musso G, Cassader M, De Michieli F, Rosina F, Orlandi F, Gambino R (2012) Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology 56(3):933\u2013942. https:\/\/doi.org\/10.1002\/hep.25739","journal-title":"Hepatology"},{"issue":"2","key":"6774_CR88","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","volume":"64","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Hull D, Guo K et al (2016) Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 64(2):399\u2013408. https:\/\/doi.org\/10.1016\/j.jhep.2015.08.038","journal-title":"J Hepatol"},{"issue":"2","key":"6774_CR89","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jhep.2012.03.013","volume":"57","author":"R Vongsuvanh","year":"2012","unstructured":"Vongsuvanh R, George J, McLeod D, van der Poorten D (2012) Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. J Hepatol 57(2):392\u2013398. https:\/\/doi.org\/10.1016\/j.jhep.2012.03.013","journal-title":"J Hepatol"},{"issue":"1","key":"6774_CR90","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12944-022-01660-8","volume":"21","author":"M Yang","year":"2022","unstructured":"Yang M, Xu Y, Hu C, Zhang S, Kuang M, Zou Y (2022) Association between hypertriglyceridemic-waist phenotype and non-alcoholic fatty liver disease: a general population-based study. Lipids Health Dis 21(1):50. https:\/\/doi.org\/10.1186\/s12944-022-01660-8","journal-title":"Lipids Health Dis"},{"issue":"4","key":"6774_CR91","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1055\/s-0028-1091980","volume":"28","author":"H Malhi","year":"2008","unstructured":"Malhi H, Gores GJ (2008) Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 28(4):360\u2013369. https:\/\/doi.org\/10.1055\/s-0028-1091980","journal-title":"Semin Liver Dis"},{"issue":"4","key":"6774_CR92","doi-asserted-by":"publisher","first-page":"E682","DOI":"10.1152\/ajpendo.00038.2002","volume":"283","author":"TK Lam","year":"2002","unstructured":"Lam TK, Yoshii H, Haber CA et al (2002) Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-delta. Am J Physiol Endocrinol Metab 283(4):E682-691. https:\/\/doi.org\/10.1152\/ajpendo.00038.2002","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"12","key":"6774_CR93","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.2337\/diabetes.54.12.3458","volume":"54","author":"G Boden","year":"2005","unstructured":"Boden G, She P, Mozzoli M et al (2005) Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes 54(12):3458\u20133465. https:\/\/doi.org\/10.2337\/diabetes.54.12.3458","journal-title":"Diabetes"},{"issue":"12","key":"6774_CR94","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1172\/JCI118742","volume":"97","author":"M Roden","year":"1996","unstructured":"Roden M, Price TB, Perseghin G et al (1996) Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97(12):2859\u20132865. https:\/\/doi.org\/10.1172\/JCI118742","journal-title":"J Clin Invest"},{"issue":"1","key":"6774_CR95","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.1152\/ajpendo.00429.2001","volume":"283","author":"G Boden","year":"2002","unstructured":"Boden G, Cheung P, Stein TP, Kresge K, Mozzoli M (2002) FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol Endocrinol Metab 283(1):E12-19. https:\/\/doi.org\/10.1152\/ajpendo.00429.2001","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"10","key":"6774_CR96","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/j.1365-2362.2007.01858.x","volume":"37","author":"C Anderwald","year":"2007","unstructured":"Anderwald C, Brunmair B, Stadlbauer K, Krebs M, Furnsinn C, Roden M (2007) Effects of free fatty acids on carbohydrate metabolism and insulin signalling in perfused rat liver. Eur J Clin Investig 37(10):774\u2013782. https:\/\/doi.org\/10.1111\/j.1365-2362.2007.01858.x","journal-title":"Eur J Clin Investig"},{"issue":"6","key":"6774_CR97","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1210\/jc.2004-2240","volume":"90","author":"E Bugianesi","year":"2005","unstructured":"Bugianesi E, Pagotto U, Manini R et al (2005) Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90(6):3498\u20133504. https:\/\/doi.org\/10.1210\/jc.2004-2240","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6774_CR98","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3390\/nu11020454","volume":"11","author":"G Fruhbeck","year":"2019","unstructured":"Fruhbeck G, Catalan V, Rodriguez A et al (2019) Adiponectin-leptin ratio is a functional biomarker of adipose tissue inflammation. Nutrients 11(2):454. https:\/\/doi.org\/10.3390\/nu11020454","journal-title":"Nutrients"},{"issue":"1","key":"6774_CR99","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.immuni.2022.11.013","volume":"56","author":"X Wang","year":"2023","unstructured":"Wang X, He Q, Zhou C et al (2023) Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development. Immunity 56(1):58-77 e11. https:\/\/doi.org\/10.1016\/j.immuni.2022.11.013","journal-title":"Immunity"},{"issue":"2","key":"6774_CR100","doi-asserted-by":"publisher","first-page":"e250056","DOI":"10.1530\/JME-25-0056","volume":"75","author":"Q Shao","year":"2025","unstructured":"Shao Q, Zhang C, Mu J et al (2025) Chronic stress-secreted glucocorticoids induce NAFLD-like changes in male rats: oxidative stress\/NLRP3 inflammasome signalling. J Mol Endocrinol 75(2):e250056. https:\/\/doi.org\/10.1530\/JME-25-0056","journal-title":"J Mol Endocrinol"},{"issue":"2","key":"6774_CR101","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s13679-024-00556-1","volume":"13","author":"SA Polyzos","year":"2024","unstructured":"Polyzos SA, Targher G (2024) Role of glucocorticoids in metabolic dysfunction-associated steatotic liver disease. Curr Obes Rep 13(2):242\u2013255. https:\/\/doi.org\/10.1007\/s13679-024-00556-1","journal-title":"Curr Obes Rep"},{"issue":"12","key":"6774_CR102","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.metabol.2011.05.001","volume":"60","author":"R Baudrand","year":"2011","unstructured":"Baudrand R, Dominguez JM, Carvajal CA et al (2011) Overexpression of hepatic 5alpha-reductase and 11beta-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue is associated with hyperinsulinemia in morbidly obese patients. Metabolism 60(12):1775\u20131780. https:\/\/doi.org\/10.1016\/j.metabol.2011.05.001","journal-title":"Metabolism"},{"key":"6774_CR103","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3389\/fendo.2015.00182","volume":"6","author":"KW Ter Horst","year":"2015","unstructured":"Ter Horst KW, Gilijamse PW, de Weijer BA et al (2015) Sexual dimorphism in hepatic, adipose tissue, and peripheral tissue insulin sensitivity in obese humans. Front Endocrinol (Lausanne) 6:182. https:\/\/doi.org\/10.3389\/fendo.2015.00182","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"6774_CR104","doi-asserted-by":"publisher","first-page":"e70137","DOI":"10.1111\/eci.70137","volume":"56","author":"AF Pina","year":"2026","unstructured":"Pina AF, Meneses MJ, Carli F et al (2026) Lipidomic profiling unveils sex differences in diabetes risk: Implications for precision medicine. Eur J Clin Investig 56(1):e70137. https:\/\/doi.org\/10.1111\/eci.70137","journal-title":"Eur J Clin Investig"},{"issue":"10","key":"6774_CR105","doi-asserted-by":"publisher","first-page":"e110405","DOI":"10.1371\/journal.pone.0110405","volume":"9","author":"P Kumar","year":"2014","unstructured":"Kumar P, Smith T, Rahman K, Thorn NE, Anania FA (2014) Adiponectin agonist ADP355 attenuates CCl4-induced liver fibrosis in mice. PLoS One 9(10):e110405. https:\/\/doi.org\/10.1371\/journal.pone.0110405","journal-title":"PLoS One"},{"issue":"1","key":"6774_CR106","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1530\/JOE-19-0321","volume":"245","author":"TM Zidon","year":"2020","unstructured":"Zidon TM, Padilla J, Fritsche KL et al (2020) Effects of ERbeta and ERalpha on OVX-induced changes in adiposity and insulin resistance. J Endocrinol 245(1):165\u2013178. https:\/\/doi.org\/10.1530\/JOE-19-0321","journal-title":"J Endocrinol"},{"issue":"3","key":"6774_CR107","doi-asserted-by":"publisher","first-page":"105661","DOI":"10.1016\/j.jbc.2024.105661","volume":"300","author":"L Li","year":"2024","unstructured":"Li L, Yao Y, Wang Y et al (2024) G protein-coupled estrogen receptor 1 ameliorates nonalcoholic steatohepatitis through targeting AMPK-dependent signaling. J Biol Chem 300(3):105661. https:\/\/doi.org\/10.1016\/j.jbc.2024.105661","journal-title":"J Biol Chem"},{"issue":"10","key":"6774_CR108","doi-asserted-by":"publisher","first-page":"E1188","DOI":"10.1152\/ajpendo.00579.2013","volume":"306","author":"L Zhu","year":"2014","unstructured":"Zhu L, Martinez MN, Emfinger CH, Palmisano BT, Stafford JM (2014) Estrogen signaling prevents diet-induced hepatic insulin resistance in male mice with obesity. Am J Physiol Endocrinol Metab 306(10):E1188-1197. https:\/\/doi.org\/10.1152\/ajpendo.00579.2013","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"6774_CR109","doi-asserted-by":"publisher","first-page":"14750","DOI":"10.1038\/s41598-021-94189-2","volume":"11","author":"J Abildgaard","year":"2021","unstructured":"Abildgaard J, Ploug T, Al-Saoudi E et al (2021) Changes in abdominal subcutaneous adipose tissue phenotype following menopause is associated with increased visceral fat mass. Sci Rep 11(1):14750. https:\/\/doi.org\/10.1038\/s41598-021-94189-2","journal-title":"Sci Rep"},{"issue":"1","key":"6774_CR110","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/hep.28514","volume":"64","author":"JS Klair","year":"2016","unstructured":"Klair JS, Yang JD, Abdelmalek MF et al (2016) A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology 64(1):85\u201391. https:\/\/doi.org\/10.1002\/hep.28514","journal-title":"Hepatology"},{"issue":"4","key":"6774_CR111","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70562","volume":"46","author":"AE Henney","year":"2026","unstructured":"Henney AE, Wilson J, Riley DR, Alam U, Cuthbertson DJ (2026) Effect of hormone replacement therapy on liver and cardiometabolic outcomes in peri-menopausal MASLD. Liver Int 46(4):e70562. https:\/\/doi.org\/10.1111\/liv.70562","journal-title":"Liver Int"},{"issue":"11","key":"6774_CR112","doi-asserted-by":"publisher","first-page":"e0186136","DOI":"10.1371\/journal.pone.0186136","volume":"12","author":"S Petta","year":"2017","unstructured":"Petta S, Ciresi A, Bianco J et al (2017) Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. PLoS One 12(11):e0186136. https:\/\/doi.org\/10.1371\/journal.pone.0186136","journal-title":"PLoS One"},{"key":"6774_CR113","doi-asserted-by":"publisher","unstructured":"Sarkar M, Yates K, Suzuki A et al (2021) Low testosterone is associated with nonalcoholic steatohepatitis and fibrosis severity in men. Clin Gastroenterol Hepatol 19(2):400-402 e402. https:\/\/doi.org\/10.1016\/j.cgh.2019.11.053","DOI":"10.1016\/j.cgh.2019.11.053"},{"issue":"1","key":"6774_CR114","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cgh.2017.08.014","volume":"16","author":"D Kim","year":"2018","unstructured":"Kim D, Kim W, Joo SK, Bae JM, Kim JH, Ahmed A (2018) Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis. Clin Gastroenterol Hepatol 16(1):123\u2013131. https:\/\/doi.org\/10.1016\/j.cgh.2017.08.014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"6774_CR115","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1210\/en.2014-1302","volume":"155","author":"BN Bohinc","year":"2014","unstructured":"Bohinc BN, Michelotti G, Xie G et al (2014) Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism. Endocrinology 155(11):4591\u20134601. https:\/\/doi.org\/10.1210\/en.2014-1302","journal-title":"Endocrinology"},{"issue":"4","key":"6774_CR116","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s42255-024-00986-0","volume":"6","author":"RA Sinha","year":"2024","unstructured":"Sinha RA, Yen PM (2024) Metabolic messengers: thyroid hormones. Nat Metab 6(4):639\u2013650. https:\/\/doi.org\/10.1038\/s42255-024-00986-0","journal-title":"Nat Metab"},{"issue":"6","key":"6774_CR117","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD et al (2024) A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"key":"6774_CR118","doi-asserted-by":"publisher","unstructured":"Stefan N, Targher G (2026) Pharmacological treatment of MASH. Diabetologia. https:\/\/doi.org\/10.1007\/s00125-026-06796-1","DOI":"10.1007\/s00125-026-06796-1"},{"issue":"6","key":"6774_CR119","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","volume":"79","author":"PN Newsome","year":"2023","unstructured":"Newsome PN, Ambery P (2023) Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver. J Hepatol 79(6):1557\u20131565. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.033","journal-title":"J Hepatol"},{"issue":"5","key":"6774_CR120","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/joim.12462","volume":"279","author":"AE Junker","year":"2016","unstructured":"Junker AE, Gluud L, Holst JJ, Knop FK, Vilsboll T (2016) Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. J Int Med 279(5):485\u2013493. https:\/\/doi.org\/10.1111\/joim.12462","journal-title":"J Int Med"},{"issue":"2","key":"6774_CR121","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.tem.2016.10.001","volume":"28","author":"G Muscogiuri","year":"2017","unstructured":"Muscogiuri G, DeFronzo RA, Gastaldelli A, Holst JJ (2017) Glucagon-like peptide-1 and the central\/peripheral nervous system: crosstalk in diabetes. Trends Endocrinol Metab 28(2):88\u2013103. https:\/\/doi.org\/10.1016\/j.tem.2016.10.001","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"6774_CR122","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s00125-012-2738-3","volume":"56","author":"M Seghieri","year":"2013","unstructured":"Seghieri M, Rebelos E, Gastaldelli A et al (2013) Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia 56(1):156\u2013161. https:\/\/doi.org\/10.1007\/s00125-012-2738-3","journal-title":"Diabetologia"},{"issue":"10","key":"6774_CR123","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.2337\/db23-0972","volume":"73","author":"G Della Pepa","year":"2024","unstructured":"Della Pepa G, Patricio BG, Carli F et al (2024) GLP-1 receptor agonist treatment improves fasting and postprandial lipidomic profiles independently of diabetes and weight loss. Diabetes 73(10):1605\u20131614. https:\/\/doi.org\/10.2337\/db23-0972","journal-title":"Diabetes"},{"issue":"S1","key":"6774_CR124","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/hep.0000000000001493","volume":"82","author":"PN Newsome","year":"2025","unstructured":"Newsome PN, Armstrong MJ, Bakulin I et al (2025) Weight-dependent and independent effects of semaglutide in participants with MASH: secondary analysis of the phase 3 ESSENCE trial. Hepatology 82(S1):S11. https:\/\/doi.org\/10.1097\/hep.0000000000001493","journal-title":"Hepatology"},{"key":"6774_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2026.03.011","author":"MJ Gonzalez-Rellan","year":"2026","unstructured":"Gonzalez-Rellan MJ, Riobello C, Fang S et al (2026) The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors. Cell Metab. https:\/\/doi.org\/10.1016\/j.cmet.2026.03.011","journal-title":"Cell Metab"},{"issue":"1","key":"6774_CR126","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/dom.70187","volume":"28","author":"M Banerjee","year":"2026","unstructured":"Banerjee M, Pal R, Pal S (2026) Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: a network meta-analysis. Diabetes Obes Metab 28(1):287\u2013295. https:\/\/doi.org\/10.1111\/dom.70187","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"6774_CR127","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.jhep.2025.03.003","volume":"82","author":"S Sabatini","year":"2025","unstructured":"Sabatini S, Gastaldelli A (2025) Metabolic effects and mechanism of action of the pan-PPAR agonist lanifibranor. J Hepatol 82(6):950\u2013952. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.003","journal-title":"J Hepatol"},{"issue":"5","key":"6774_CR128","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jhep.2023.07.004","volume":"79","author":"B Staels","year":"2023","unstructured":"Staels B, Butruille L, Francque S (2023) Treating NASH by targeting peroxisome proliferator-activated receptors. J Hepatol 79(5):1302\u20131316. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.004","journal-title":"J Hepatol"},{"issue":"10","key":"6774_CR129","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.2337\/dc05-2445","volume":"29","author":"A Gastaldelli","year":"2006","unstructured":"Gastaldelli A, Miyazaki Y, Mahankali A et al (2006) The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care 29(10):2275\u20132281. https:\/\/doi.org\/10.2337\/dc05-2445","journal-title":"Diabetes Care"},{"key":"6774_CR130","doi-asserted-by":"publisher","unstructured":"Gastaldelli A, Sabatini S, Carli F et al (2021) PPAR-gamma-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. Liver Int 41(11):2659\u20132670. https:\/\/doi.org\/10.1111\/liv.15005","DOI":"10.1111\/liv.15005"},{"key":"6774_CR131","doi-asserted-by":"publisher","first-page":"108984","DOI":"10.1016\/j.diabres.2021.108984","volume":"178","author":"G Della Pepa","year":"2021","unstructured":"Della Pepa G, Russo M, Vitale M et al (2021) Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCAIT randomised trial. Diabetes Res Clin Pract 178:108984. https:\/\/doi.org\/10.1016\/j.diabres.2021.108984","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"6774_CR132","doi-asserted-by":"publisher","first-page":"115165","DOI":"10.1016\/j.celrep.2024.115165","volume":"44","author":"S Zhao","year":"2025","unstructured":"Zhao S, Zhu Q, Lee WH et al (2025) The adiponectin-PPARgamma axis in hepatic stellate cells regulates liver fibrosis. Cell Rep 44(1):115165. https:\/\/doi.org\/10.1016\/j.celrep.2024.115165","journal-title":"Cell Rep"},{"issue":"5","key":"6774_CR133","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1097\/HEP.0000000000000182","volume":"78","author":"L Gong","year":"2023","unstructured":"Gong L, Wei F, Gonzalez FJ, Li G (2023) Hepatic fibrosis: targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines. Hepatology 78(5):1625\u20131653. https:\/\/doi.org\/10.1097\/HEP.0000000000000182","journal-title":"Hepatology"},{"key":"6774_CR134","doi-asserted-by":"publisher","first-page":"117303","DOI":"10.1016\/j.biopha.2024.117303","volume":"179","author":"M Zhang","year":"2024","unstructured":"Zhang M, Barroso E, Pena L et al (2024) PPARbeta\/delta attenuates hepatic fibrosis by reducing SMAD3 phosphorylation and p300 levels via AMPK in hepatic stellate cells. Biomed Pharmacother 179:117303. https:\/\/doi.org\/10.1016\/j.biopha.2024.117303","journal-title":"Biomed Pharmacother"},{"key":"6774_CR135","doi-asserted-by":"publisher","unstructured":"Ni XX, Ji PX, Chen YX et al (2022) Regulation of the macrophage-hepatic stellate cell interaction by targeting macrophage peroxisome proliferator-activated receptor gamma to prevent non-alcoholic steatohepatitis progression in mice. Liver Int 42(12):2696\u20132712. https:\/\/doi.org\/10.1111\/liv.15441","DOI":"10.1111\/liv.15441"},{"key":"6774_CR136","doi-asserted-by":"publisher","first-page":"101152","DOI":"10.1016\/j.molmet.2020.101152","volume":"46","author":"S Talukdar","year":"2021","unstructured":"Talukdar S, Kharitonenkov A (2021) FGF19 and FGF21: In NASH we trust. Mol Metab 46:101152. https:\/\/doi.org\/10.1016\/j.molmet.2020.101152","journal-title":"Mol Metab"},{"issue":"10","key":"6774_CR137","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","volume":"67","author":"N Jiao","year":"2018","unstructured":"Jiao N, Baker SS, Chapa-Rodriguez A et al (2018) Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut 67(10):1881. https:\/\/doi.org\/10.1136\/gutjnl-2017-314307","journal-title":"Gut"},{"issue":"5","key":"6774_CR138","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jhep.2016.01.002","volume":"64","author":"PK Luukkonen","year":"2016","unstructured":"Luukkonen PK, Zhou Y, Sadevirta S et al (2016) Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J Hepatol 64(5):1167\u20131175. https:\/\/doi.org\/10.1016\/j.jhep.2016.01.002","journal-title":"J Hepatol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06774-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06774-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06774-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:39:30Z","timestamp":1790771970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-026-06774-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":138,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["6774"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06774-7","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Open access funding provided by Consiglio Nazionale Delle Ricerche (CNR) within the CRUI-CARE Agreement. Work in the authors\u2019 laboratories is supported by the European Union\u2019s Horizon Europe Research and Innovation Programme for the project \u2018PAS GRAS: De-risking metabolic, environmental and behavioral determinants of obesity in children, adolescents and young adults\u2019 (n. 101080329) (to AG and MPM); the Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia \u2013 iNOVA4Health (UIDB\/Multi\/04462\/2020) and LS4FUTURE Associated Laboratory (LA\/P\/0087\/2020) (to MPM); and the Horizon Europe Research and Innovation Programme (IHI JU) for the project \u2018GRIPonMASH: Global Research Initiative for Patient screening on MASH\u2019 (n. 101132946) (to AG). The IHI JU receives support from the European Union\u2019s Horizon Europe Research and Innovation Programme and COCIR, Efpia, EuropaBio, MedTech Europe, Vaccines Europe and Mercodia Aktiebolag, Metadeq Limited and Julius Clinical Research BV. This review reflects the authors\u2019 views only and does not necessarily reflect those of the aforementioned parties; none of the aforementioned parties can be held responsible for them.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"AG is a consultant for Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk and Regeneron Pharmaceuticals; has received lecture fees from Boehringer Ingelheim, Merck Sharp & Dohme, Madrigal and Novo Nordisk; and has received educational grants from Eli Lilly, Boehringer Ingelheim, Echosens and Mercodia. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.","order":2,"name":"Ethics","label":"Authors\u2019 relationships and activities","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"AG conceived and wrote the first draft of the manuscript with inputs from MPM and ES. All authors were responsible for reviewing the article critically for important intellectual content. All authors approved the version to be published.","order":3,"name":"Ethics","label":"Contribution statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}